drugset
drugset / Trial / NCT03218163

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

NCT03218163 ↗

Phase 2 Terminated 1 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaSingle-groupOpen-labelTreatment

Summary

Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM) patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT) followed by maintenance therapy with MEDI-551.

Timeline

Start
2017-09-27
Primary completion
2018-04-15
Completion
2018-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Inebilizumab Monoclonal antibody 4 mg/kg Intravenous

Indications

plasma cell myeloma